Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
Endocr Rev. 2016 Oct;37(5):521-547. Epub 2016 Sep 2.
Tebben PJ1, Singh RJ1, Kumar R1.
- Vitamin D - Comparing Symptoms of Hypercalcemia with Low Magnesium - Sept 2015
- Search VitaminDWiki for HYPERCALCEMIA 1480 results as of Oct 2019
- No risk of hypercalcemia with prolonged 10000 IU of vitamin D3 – July 2010
- Hypercalcemia in critically ill patients taking 10,000 IU of vitamin D (many solutions) – Oct 2019
- No correlation found between hypercalcemia and high level of vitamin D – March 2021
- Vitamin D supplementation and fewer kidney stones – meta-analysis of RCT Sept 2016
Download the PDF from VitaminDWiki
Hypercalcemia occurs in up to 4% of the population in association with
- malignancy,
- primary hyperparathyroidism,
- ingestion of excessive calcium and/or vitamin D,
- ectopic production of 1,25-dihydroxyvitamin D [1,25(OH)2D], and
- impaired degradation of 1,25(OH)2D.
The ingestion of excessive amounts of vitamin D3 (or vitamin D2) results in hypercalcemia and hypercalciuria due to the formation of supraphysiological amounts of 25-hydroxyvitamin D [25(OH)D] that bind to the vitamin D receptor, albeit with lower affinity than the active form of the vitamin, 1,25(OH)2D, and the formation of 5,6-trans 25(OH)D, which binds to the vitamin D receptor more tightly than 25(OH)D.
In patients with granulomatous disease such as sarcoidosis or tuberculosis and tumors such as lymphomas, hypercalcemia occurs as a result of the activity of ectopic 25(OH)D-1-hydroxylase (CYP27B1) expressed in macrophages or tumor cells and the formation of excessive amounts of 1,25(OH)2D.
Recent work has identified a novel cause of non-PTH-mediated hypercalcemia that occurs when the degradation of 1,25(OH)2D is impaired as a result of mutations of the 1,25(OH)2D-24-hydroxylase cytochrome P450 (CYP24A1). Patients with biallelic and, in some instances, monoallelic mutations of the CYP24A1 gene have elevated serum calcium concentrations associated with elevated serum 1,25(OH)2D, suppressed PTH concentrations, hypercalciuria, nephrocalcinosis, nephrolithiasis, and on occasion, reduced bone density. Of interest, first-time calcium renal stone formers have elevated 1,25(OH)2D and evidence of impaired 24-hydroxylase-mediated 1,25(OH)2D degradation. We will describe the biochemical processes associated with the synthesis and degradation of various vitamin D metabolites, the clinical features of the vitamin D-mediated hypercalcemia, their biochemical diagnosis, and treatment.
PMID: 27588937 PMCID: PMC5045493 [Available on 2017-10-01] DOI: 10.1210/er.2016-1070